Business Context and Reporting Period
This Form 8-K, dated March 23, 2022, reports on events occurring on March 22, 2022, for Collegium Pharmaceutical, Inc. The filing primarily announces the successful completion of the acquisition of BioDelivery Sciences International, Inc. (BDSI) via a tender offer and subsequent merger. Additionally, the Company entered into a new material definitive loan agreement to finance the transaction and announced a change in executive leadership.
Key Financial Metrics and Transaction Details
- Acquisition Consideration: The aggregate consideration to complete the tender offer and merger is approximately $607 million (excluding transaction fees and expenses).
- Offer Price: $5.60 per share in cash for BDSI common stock.
- Tender Offer Results: 74,780,700 shares were validly tendered, representing approximately 72.44% of outstanding shares. This satisfied the minimum condition of greater than 50% ownership.
- Debt Financing: The Company entered into a $650 million secured term loan.
- Loan Terms:
- Maturity: 48 months from closing.
- Interest Rate: LIBOR (with a 1.20% floor) plus a 7.5% margin.
- Amortization: $100 million in the first year; the remaining $550 million amortizes in equal quarterly installments over the subsequent three years.
- Collateral: Secured by substantially all assets of the Company and its material domestic subsidiaries.
- Liquidity and Cash Flow: Proceeds from the new term loan were used to repay the Company's existing term loan, repay outstanding BDSI indebtedness, and fund a portion of the acquisition consideration. Specific cash balance figures are not provided in this filing.
Material Changes Versus Prior Period
This filing represents a material change in the Company's capital structure and asset base due to the acquisition of BDSI. Key changes include:
- Ownership Structure: BDSI is now a wholly-owned subsidiary of Collegium Pharmaceutical.
- Debt Profile: Replacement of existing debt with a new $650 million term loan carrying a higher interest margin (7.5% over LIBOR) and specific amortization requirements.
- Executive Leadership: Dr. Thomas Smith was appointed Executive Vice President and Chief Medical Officer, replacing Dr. Richard Malamut, who ceased service on March 23, 2022.
- Equity Compensation: All outstanding BDSI stock options, restricted stock units (RSUs), and warrants were converted to cash or cancelled based on the $5.60 offer price.
Guidance, Outlook, Risks, and Contingencies
Management Commentary and Outlook: The filing confirms the successful closing of the transaction as of 5:00 p.m. on March 22, 2022. No specific financial guidance or revenue outlook for the combined entity is provided in this document.
Risks and Contingencies:
- Covenant Compliance: The new Loan Agreement includes covenants limiting the Company's ability to incur additional indebtedness, make acquisitions, or dispose of assets outside the ordinary course of business. Failure to comply constitutes an event of default.
- Default Remedies: In the event of default, lenders may accelerate repayment and execute upon the collateral securing the obligations.
- Financial Reporting: Audited financial statements of BDSI and pro forma financial information reflecting the merger are not included in this filing but will be submitted via amendment within 71 calendar days.
Important Facts for Investor Verification
- Verify the final pro forma financial statements to understand the combined entity's leverage and liquidity position post-acquisition.
- Review the full text of the Amended and Restated Loan Agreement (Exhibit 10.1) to assess the specific restrictive covenants and default triggers.
- Monitor the integration of BDSI's operations and the impact of the new debt service obligations ($100 million due in the first year) on future cash flows.
- Confirm the status of the remaining BDSI shares not tendered in the offer, which were converted to cash at the $5.60 price.